Retatrutide has become one of the most closely watched investigational compounds in metabolic research. Much of the attention comes from its unusual mechanism: instead of targeting only one hormone receptor, retatrutide activates three — GIP, GLP-1 and glucagon receptors. That makes the question “How is retatrutide different from a GLP-1?” particularly important. The answer is not simply that it is a stronger GLP-1. Retatrutide is a different type of multi-receptor agonist be